4 Takeaways From FDA's Biosimilars Briefing
A top U.S. Food and Drug Administration official briefed U.S. senators Thursday about looming developments in regulating biosimilars, saying that new guidances are coming soon and that labeling and naming policies...To view the full article, register now.
Already a subscriber? Click here to view full article